慢性乙型肝炎病毒感染者血清透明质酸与FibroScan检测相关性研究

The research on correlation between hyaluronic acid from Chronic hepatitis B virus infection serum and FibroScan test

目的探讨慢性乙型肝炎病毒感染者血清透明质酸值、FibroScan检测值之间的相关性。方法选取唐都医院感染科各种慢性乙型肝炎病毒感染者102例,其中慢性乙型病毒性肝炎患者58例,乙型肝炎肝硬化患者44例,联合检测患者血清透明质酸值和FibroScan值,对结果进行相关性及差异性统计分析。结果慢性乙型病毒性肝炎患者血清透明质酸检测值与FibroScan检测值呈正相关;乙型肝炎肝硬化患者血清透明质酸检测值与Fibroscan检测值呈正相关;乙型肝炎肝硬化患者血清透明质酸检测值、FibroScan检测值与慢性乙型病毒性肝炎患者组分别比较,两者之间的差异有统计学意义(P<0.05。结论不同慢性乙型肝炎病毒感染者血清透明质酸检测值与FibroScan检测值存在相关性,为根据FibroScan检测值给血清透明质酸检测值制定相应肝纤维化分期的界值范围提供了一定依据,血清透明质酸检测联合Fibroscan检测有利于更好的动态监测慢性乙型肝炎病毒感染者肝组织纤维化的进展,及时预测早期肝组织纤维化,提高肝纤维化诊断的准确率,进一步指导慢性乙型肝炎病毒感染者有效抗肝纤维化治疗。

Objective To explore the eorrelation between hyaluronic acid from chronic hepatitis B virus infection serum and value of FibroScan test. Methods 102 cases chronic hepatitis B virus infection patients from Tangdu Hospital was included, 58 patients with chronic hepatitis B and 44 patients with hepatitis B cirrhosis. The serum hyaluronic acid and FibroScan value in these patients were tested, then the collection data were studied retrospectively. Results 1. The serum hyaluronic acid value and the FibroScan were positively correlated in patients with chronic hepatitis B; 2. The serum hyaluronic acid value and the FibroScan were positively were correlated in patients with hepatitis B cirrhosis ; 3. It had statistically significant differences between chronic hepatitis B and hepatitis B cirrhosis patients in the serum hyaluronic acid value and the FibroScan. Conclusion It had correlation between hyaluronic acid from Chronic hepatitis B virus infection serum and value of FibroScan test, according to that the value of FibroScan test can provide certain basis for serum hyaluronic acid value to formulate the hepatic fibrosis staging ranges, on the condition that combining the serum hyalutonic acid detection with Fibroscan testing, it is helpful for dynamic monitoring in chronic hepatitis B virus infection liver tissue fibrosis progression, timely forecast early liver fibrosis hepatic fibrosis, and improving the accuracy rate of diagnosis, then guidancing the effective therapy of liver fibrosis for patients with chronic hepatitis B virus infection.